Recurrent Lung Cancer – Non-Small Cell

Many Late Stage Lung Cancer Patients do not Receive Treatment (01-24-2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (10-25-2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (10-25-2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (09-13-2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (06-7-2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be... Continue Reading

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer (12-3-2015)

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (11-10-2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published... Continue Reading

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer (09-15-2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are... Continue Reading

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer (09-14-2015)

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday... Continue Reading

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer (09-10-2015)

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies... Continue Reading

Next Page »